IDEXX Laboratories Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
IDEXX Laboratories hat ein Gesamteigenkapital von $1.6B und eine Gesamtverschuldung von $945.8M, wodurch sich der Verschuldungsgrad auf 60.3% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $3.4B bzw. $1.8B. IDEXX Laboratories Das EBIT des Unternehmens beträgt $1.1B, so dass der Zinsdeckungsgrad 41.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $397.4M.
Wichtige Informationen
60.3%
Verhältnis von Schulden zu Eigenkapital
US$945.78m
Verschuldung
| Zinsdeckungsgrad | 41.8x |
| Bargeld | US$397.43m |
| Eigenkapital | US$1.57b |
| Gesamtverbindlichkeiten | US$1.78b |
| Gesamtvermögen | US$3.35b |
Jüngste Berichte zur Finanzlage
IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24Recent updates
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?
Apr 23With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting
Apr 09Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Mar 07IDEXX Laboratories And Its Real Value
Feb 02Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: IDXX's short term assets ($1.5B) exceed its short term liabilities ($956.9M).
Langfristige Verbindlichkeiten: IDXXDie kurzfristigen Vermögenswerte des Unternehmens ($1.5B) übersteigen seine langfristigen Verbindlichkeiten ($827.7M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: IDXXDie Nettoverschuldung im Verhältnis zum Eigenkapital (35%) wird als zufriedenstellend angesehen.
Schulden abbauen: IDXX Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 2017.2% auf 60.3% zurückgegangen.
Schuldendeckung: IDXXDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (97.4%).
Zinsdeckung: Die Zinszahlungen für die Schulden von IDXX sind durch das EBIT gut gedeckt (41.8x coverage).